Oxford BioMedica Licenses Retroviral Ex Vivo Gene Delivery Technology to MolMed SpA

15-Dec-2004

Oxford BioMedica and MolMed SpA (Milan, Italy) today announced a licence agreement for Oxford BioMedica's retroviral ex vivo gene delivery technology. The agreement provides MolMed with rights to utilise this technology in the development of MolMed's product pipeline. Under the agreement, Oxford BioMedica receives an upfront licence fee and annual maintenance payments. In addition, Oxford BioMedica will receive payments on the achievement of clinical and regulatory milestones by MolMed and product royalties. Further financial details were not disclosed.

The retroviral ex vivo gene delivery technology combines Oxford BioMedica's technology with some of the gene therapy technology acquired from Chiron Corporation in June this year.

Oxford BioMedica's CEO, Professor Alan Kingsman, said: "We are delighted to welcome MolMed to the list of Oxford BioMedica's technology licensees. This agreement provides further evidence of the breadth and strength of our proprietary gene delivery technology."

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world
Topic world Gene therapy

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.